Sauny Sewell

Director of Clinical Affairs, Triple Helix Science

Patient care and long-term follow-up in gene therapy and healthspan medicine

Roughly monthly. Unsubscribe any time.

Contact for media →

What Sauny writes about

Sauny Sewell writes about what patient-first care looks like in practice, from first assessment through the years of follow-up that keep people well. She covers intake and treatment planning, why long-term follow-up so often slips and what it takes to keep it, and palliative care and symptom management.

Sauny's newsletter, The Patient's Side, comes out roughly monthly, with notes on gene therapy and preventative care, from the patient's side.

Board-certified family nurse practitioner and advanced certified hospice and palliative nurse; former System Director of Nursing at Bozeman Health.

Newsletters

The Patient's SideSauny's newsletter

First issue coming soon

Comes out roughly monthly, with notes on gene therapy and preventative care, from the patient's side.

Sign up now to get the first issue. Unsubscribe any time.

Media reaction

Patient experience in gene therapy

"Too often the patient is an afterthought in next-generation medicine. We talk about the science of gene therapy, but far less about what it's like to receive it. Nurse-led care that prepares patients and stays with them for years is one of the gaps we must close if gene therapy is going to reach more people."
Sauny SewellSauny Sewell, Director of Clinical Affairs, Triple Helix Science20 Oct 2026

Areas of expertise

All areas →
Gene TherapyLongevityClinical GovernancePatient CareModel of Care Design

Most asked

Who is Sauny Sewell?
Sauny Sewell is Director of Clinical Affairs at Triple Helix Science, a precision medicine company working across gene therapy, regenerative medicine, stem cell science and longevity science. Sauny Sewell's remit is patient care and long-term follow-up in gene therapy and healthspan medicine, together with the clinical governance that sits around both. Sauny Sewell speaks on gene therapy, longevity, clinical governance and patient care.
What does Triple Helix Science do, and what is Sauny Sewell's role there?
Triple Helix Science develops proprietary, IP-protected therapeutic protocols across eight therapeutic areas, from longevity and metabolic health to neurodegeneration and oncology, and works with governments, sovereign health systems, research universities and enterprise pharmaceutical organisations rather than selling direct to consumers. Sauny Sewell, as Director of Clinical Affairs, is responsible for patient care standards and long-term follow-up as those protocols move into clinical settings.
What will Sauny Sewell talk to journalists about?
Sauny Sewell comments on patient care, consent, clinical governance and long-term follow-up in gene therapy and healthspan medicine, including how healthspan outcomes are measured after an intervention.
What do most gene therapy programmes get wrong about follow-up?
Treating follow-up as aftercare is the error Sauny Sewell sees most often in gene therapy. A durable genetic intervention changes what a patient is living with for years, so Sauny Sewell argues the follow-up schedule is part of the therapy itself and belongs in the protocol at design stage, alongside consent that is revisited rather than signed once and filed.

Contact for media

Reach Sauny directly for comment, background or an interview, on deadline or ahead of one.

Straight to the Triple Helix Science press team.